Literature DB >> 16219895

Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.

Marni J Grant, Ross J Baldessarini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219895     DOI: 10.1345/aph.1G255

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  7 in total

1.  A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole.

Authors:  Hannah E Brown; Alice W Flaherty; Donald C Goff; Oliver Freudenreich
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

3.  Tardive dyskinesia: treatment with aripiprazole.

Authors:  Na-Ri Kang; Moon-Doo Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

4.  Treatment of tardive dyskinesia with aripiprazole.

Authors:  Ricardo S Osorio; L Agüera-Ortiz; A Hurtado de Mendoza; I Ramos; T Palomo
Journal:  Neurotox Res       Date:  2009-10-14       Impact factor: 3.911

5.  Aripiprazole (abilify) and tardive dyskinesia.

Authors:  Thomas Schwartz; Shafi Raza
Journal:  P T       Date:  2008-01

Review 6.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Tardive Dystonia Related with Aripiprazole.

Authors:  Sunghwan Kim; Seung-Yup Lee; MinSeob Kim; Kyoung-Uk Lee
Journal:  Psychiatry Investig       Date:  2017-05-16       Impact factor: 2.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.